ALIROCUMAB, MONOCLONAL ANTIBODY TO PCSK9, DOSE-DEPENDENTLY DECREASES ATHEROSCLEROSIS, IMPROVES PLAQUE STABILITY AND SHOWS ADDITIVE EFFECTS WITH ATORVASTATIN IN APOE*3LEIDEN.CETP MICE

Author(s):
Hoorn, J.W.A. van der; Kuhnast, S.; Pieterman, E.J.; Hoek, A.M. van den; Sasiela, W.J.; Gusarova, V.; Peyman, A.; Schaefer, H.L.; Schwahn, U.; Jukema, J.W. (0000-0002-3246-8359); Princen, H.M.G.
Published
2014
Publication type
Article / Letter to editor
Date issued
2014-08-31
Language
English
Is part of
Atherosclerosis (2014), Vol. 235, no. 2, p. E19-E19
hdl
1887/103247